Form 4: Theravance Biopharma Executive Reports Share Disposal for Tax Obligations
SEC Form 4 Filing
Brett A. Grimaud, SVP, General Counsel, and Secretary of Theravance Biopharma, Inc., disposed of shares to cover tax obligations related to vesting restricted stock units.
Summary
- On February 20, 2025, Brett A. Grimaud, a senior executive at Theravance Biopharma, Inc., disposed of 14,534 ordinary shares.
- The shares were disposed of to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
- The transaction was conducted with the issuer and did not involve an open market transaction.
- The price per share was $9.66.
- Following the transaction, Grimaud beneficially owns 318,811 ordinary shares.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard transaction related to executive compensation and doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
This is a routine Form 4 filing, which is common for corporate insiders who have stock transactions. It doesn't necessarily indicate a change in the company's outlook, but rather reflects an executive's personal financial management related to equity compensation.
Key Dates
| Date | Description |
|---|---|
| 02/20/2025 | Date of share disposal transaction |
| 02/24/2025 | Date of signature on the Form 4 filing |
Keywords
Theravance Biopharma, TBPH, share disposal, Form 4, insider trading, Brett A. Grimaud, restricted stock units, tax obligations
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.